Evolus (EOLS) Competitors

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Which has better valuation & earnings, ARWR or EOLS?

Evolus has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$3.55M	798.79	-$599.49M	-$1.28	-16.02
Evolus	$277.94M	1.57	-$50.42M	-$0.98	-6.87

Does the media refer more to ARWR or EOLS?

In the previous week, Arrowhead Pharmaceuticals had 22 more articles in the media than Evolus. MarketBeat recorded 30 mentions for Arrowhead Pharmaceuticals and 8 mentions for Evolus. Arrowhead Pharmaceuticals' average media sentiment score of 0.70 beat Evolus' score of 0.46 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Evolus	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, ARWR or EOLS?

Arrowhead Pharmaceuticals has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Do analysts recommend ARWR or EOLS?

Arrowhead Pharmaceuticals currently has a consensus target price of $43.14, indicating a potential upside of 110.35%. Evolus has a consensus target price of $21.25, indicating a potential upside of 215.75%. Given Evolus' higher possible upside, analysts plainly believe Evolus is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Evolus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Do insiders & institutionals hold more shares of ARWR or EOLS?

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 5.9% of Evolus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Is ARWR or EOLS more profitable?

Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Evolus' net margin of -22.31%. Arrowhead Pharmaceuticals' return on equity of -40.91% beat Evolus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	N/A	-40.91%	-11.62%
Evolus	-22.31%	-759.04%	-24.63%

Summary

Arrowhead Pharmaceuticals beats Evolus on 9 of the 17 factors compared between the two stocks.